source
- Otsuka receives FDA approval for Simtriyo, first norepinephrine-dopamine-serotonin reuptake inhibitor for ADHDOtsuka Pharmaceutical announced that the FDA has approved its daily pill centanafadine, branded as Simtriyo, for the treatment of attention-deficit hyperactivity disorder in patients six years and…
- Global HIV funding drops 18%, raising fears of epidemic resurgenceA new UNAIDS report warns that the world could see a rebound of HIV infections after donor financing fell sharply last year. Government contributions dropped by more than $1.5 billion to $7.3 bill…